Trials / Available
AvailableNCT05028166
Individual Patient Compassionate Use of Mirdametinib
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- SpringWorks Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- —
Summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Conditions
- Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
- Histiocytic Neoplasm
- Other MAP-K Pathway Driven Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirdametinib (MEK Inhibitor) | Patients will receive oral mirdametinib. |
Timeline
- First posted
- 2021-08-31
- Last updated
- 2026-03-27
Source: ClinicalTrials.gov record NCT05028166. Inclusion in this directory is not an endorsement.